Roche’s Rituximab Gains Two New Indications In The EU
This article was originally published in The Pink Sheet Daily
Executive Summary
MabThera, marketed by Genentech/Biogen Idec in the U.S. as Rituxan, is now approved in Europe for maintenance NHL and RA.
You may also be interested in...
NICE Adds Arthritis Drugs To Fast Track Appraisal Pathway
Clinical and cost effectiveness of Rituxan, Orencia, Humira, and Arava to be evaluated under single technology appraisal process.
NICE Adds Arthritis Drugs To Fast Track Appraisal Pathway
Clinical and cost effectiveness of Rituxan, Orencia, Humira, and Arava to be evaluated under single technology appraisal process.
Rituxan Comes In Like A Lion With Two New Indications
FDA clears Genentech/Biogen Idec’s oncologic Rituxan for rheumatoid arthritis weeks after it was approved for first-line non-Hodgkins lymphoma.